On May 1, 2024, Cassava Sciences, Inc., a clinical-stage biotechnology company, announced that May 2, 2024, would be the last day for trading its SAVAW warrants on NASDAQ. The company also reminded warrant holders that they have until 5pm New York time on May 6, 2024, to cash-exercise their warrants at $33.00 each, receiving 1.5 shares of common stock per warrant. After this deadline, any unexercised warrants will be redeemed by the company on May 7, 2024, for $0.001 per warrant. Cassava Sciences has provided a Notice of Guaranteed Delivery to assist warrant holders in exercising their warrants if their financial institution cannot complete the process timely. The company's press release and the Notice are available on its website and have been included in its SEC Form 8-K filing dated May 1, 2024. The announcement also refers to the company's mission to detect and treat neurodegenerative diseases, such as Alzheimer's disease.

On May 1, 2024, Cassava Sciences, Inc., a clinical-stage biotechnology company, announced that May 2, 2024, would be the last day for trading its SAVAW warrants on NASDAQ. The company also reminded warrant holders that they have until 5pm New York time on May 6, 2024, to cash-exercise their warrants at $33.00 each, receiving 1.5 shares of common stock per warrant. After this deadline, any unexercised warrants will be redeemed by the company on May 7, 2024, for $0.001 per warrant. Cassava Sciences has provided a Notice of Guaranteed Delivery to assist warrant holders in exercising their warrants if their financial institution cannot complete the process timely. The company's press release and the Notice are available on its website and have been included in its SEC Form 8-K filing dated May 1, 2024. The announcement also refers to the company's mission to detect and treat neurodegenerative diseases, such as Alzheimer's disease.